ASCO 2026
Wassim McHayleh, MD, FACP, MBA, on Elacestrant Plus Capivasertib in ER-Positive/HER2-Negative Advanced Breast Cancer: Update From ELEVATE
Wassim McHayleh, MD, FACP, MBA, of AdventHealth Cancer Institute, provides an update from the phase Ib/II ELEVATE trial, an open-label umbrella study. This report focuses on updated safety and prelimi...
Antonio Llombart-Cussac, MD, PhD, on ADELA: Elacestrant Plus Everolimus in ESR1-Mutated ER-Positive HER2-Negative Advanced Breast Cancer
Antonio Llombart-Cussac, MD, PhD, of Medica Scientia Innovation Research (MEDSIR), discusses the ongoing ADELA study, a double-blind, placebo-controlled, randomized phase III trial of elacestrant plus...
Daniel A. Ermann, MD, on First-Line Therapy for CLL: Real-World Outcomes Among Medicare Beneficiaries
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, presents findings from a retrospective cohort study which used a large U.S. database to evaluate clinical out...
Daniel A. Ermann, MD, on Two Agents in Treatment-Naive Patients With CLL: Real-World Treatment and Survival Outcomes
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, reviews data from a retrospective analysis that compared the real-world effectiveness of monotherapy first-li...
Michael G. Fradley, MD: How Does Atrial Fibrillation Affect Outcomes and Health-Care Utilization Among Patients With CLL?
Michael G. Fradley, MD, of the University of Pennsylvania School of Medicine, discusses findings from a study which evaluated impact of atrial fibrillation on cardiovascular outcomes (stroke, bleeding...
Jennifer A. Woyach, MD, on Pretreated Relapsed or Refractory CLL/SLL: Ongoing ROCKET-CLL Trial
Jennifer A. Woyach, MD, of The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, discusses the ongoing, actively recruiting ROCKET-CLL trial, which...
Paolo Tarantino, MD, PhD, on HER2-Positive Metastatic Breast Cancer: Overall Survival by Genomic Profile
Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute, reviews the results of a large clinicogenomic database study that looked at overall survival by genomic profile among patients with HER2-posi...
François-Clément Bidard, MD, PhD, on Advanced Breast Cancer With Emergent ESR1 Mutations: First-Line Option
François-Clément Bidard, MD, PhD, of Institut Curie, presents final progression-free survival 2 findings from the phase III SERENA-6 trial, which investigated the efficacy of camizestrant, a selective...
Gerneiva Parkinson, MD, on Time on Systemic Therapy for Patients With HR-Positive Breast Cancer and a Pathogenic Variant
Gerneiva Parkinson, MD, of Stanford Cancer Institute, discusses time on treatment for systemic therapies among women with hormone receptor (HR)-positive breast cancer and a pathogenic variant in BRCA1...
Siddhartha Yadav, MBBS, MD, on Germline Pathogenic Variants Among Patients With Breast or Ovarian Cancer
Siddhartha Yadav, MBBS, MD, of Mayo Clinic Rochester, talks about a real-world evaluation of germline pathogenic variants in cancer predisposition genes in unselected South Asian women with breast or ...
Martine J. Piccart-Gebhart, MD, PhD, on Personalizing Treatments in HR-Positive/HER2-Negative Breast Cancer
Martine J. Piccart-Gebhart, MD, PhD, of Jules Bordet Institute, Université Libre de Bruxelles, reviews multiple abstracts discussing avenues of personalized treatment for patients with hormone recepto...
Elizabeth Smyth, MD, on New Data in Gastric/Gastroesophageal Cancers
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan ...
Katharina C. Kaehler, MD, on Daromun in Resectable Locally Advanced Melanoma: Trial Updates
Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of t...
Dor Abelman, BS, on Multiple Myeloma: cfDNA WGS vs Plasma Proteomics for Minimally Invasive MRD Assessment
Dor Abelman, BS, of the University of Toronto, reviews results of a comparison of two minimally invasive measurable residual disease (MRD) assays—BM-informed cfDNA whole-genome sequencing (cfWGS) and ...
Jame Abraham, MD, FACP, on Update on the DESTINY-Breast05 Trial
Jame Abraham, MD, FACP, of Cleveland Clinic, provides an update on the DESTINY-Breast05 trial, which is an ongoing phase III trial investigating postneoadjuvant trastuzumab deruxtecan (T-DXd) as compa...
Jame Abraham, MD, FACP, on First Results of the OPTIMA Trial in Breast Cancer: Expert Perspective
Jame Abraham, MD, FACP, of Cleveland Clinic, offers his thoughts on findings from OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), an international random...
Krishnansu S. Tewari, MD, on Gynecologic Cancers: Expert Perspective on Major Data
Krishnansu S. Tewari, MD, of the University of California, Irvine, provides commentary on research presented in the oral abstract and rapid oral abstract sessions for gynecologic cancer, focusing on t...
Rami Manochakian, MD, FASCO, on Updates on SCLC: No Longer Too Small to Ignore
Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, summarizes an educational session at ASCO that reviewed the state of the field of small cell lung cancer (SCLC) treatment. After decades of limited...
Christine Lovly, MD, PhD, FASCO, on Adjuvant Selpercatinib in RET Fusion–Positive Early-Stage NSCLC: Expert Perspective
Christine Lovly, MD, PhD, FASCO, of City of Hope, offers her thoughs on the findings of the LIBRETTO-432 trial, which found improved event-free survival with adjuvant selpercatinib after definitive th...
Elizabeth McDonald, MD, PhD, on GLP-1 Agonists and Breast Cancer Incidence
Elizabeth McDonald, MD, PhD, of the University of Pennsylvania, discusses results from a retrospective cohort study that showed that the use of GLP-1 treatment was associated with a significantly lowe...
Mali Barbi, MD, MS, on Endometrial Cancer: Data in dMMR Disease and B7-H4 ADCs for Advanced Disease
Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarli...
Suneel Kamath, MD, on Correlation Between Blood and Tissue Tumor Mutation Burden
Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testin...
Daneng Li, MD, on Tegavivint in Advanced HCC
Daneng Li, MD, of City of Hope, discusses dose-finding results from a phase I/II trial of tegavivint, a downstream Wnt/β-catenin inhibitor, in patients with advanced hepatocellular carcinoma (HCC) (Ab...
Joel W. Neal, MD, PhD, on the CHRYSALIS-2 Study in Atypical EGFR-Mutated Advanced NSCLC
Joel W. Neal, MD, PhD, of Stanford Cancer Institute, discusses updated overall survival data from cohort C of the CHRYSALIS-2 trial, which looked at first-line amivantamab plus lazertinib in previousl...
Hannah L. Kenny, MD, and Joseph M. Curry, MD, on BCC of the Head and Neck: Neoadjuvant Cemiplimab
Hannah L. Kenny, MD, and Joseph M. Curry, MD, both of Thomas Jefferson University Hospital, discuss results of a phase II trial of neoadjuvant cemiplimab-rwlc in patients with hedgehog inhibitor–naive...
Gopa Iyer, MD, on LY4052031 for Advanced or Metastatic Urothelial Carcinoma
Gopa Iyer, MD, of Memorial Sloan Kettering Cancer Center, presents initial results from the phase I NEXUS-01 study, which evaluated LY4052031, an antibody-drug conjugate targeting Nectin-4, in patient...
Dai Chihara, MD, on a Regimen for Older, Unfit, or Frail Patients With Newly Diagnosed DLBCL
Dai Chihara, MD, of The University of Texas MD Anderson Cancer Center, reviews results from an open-label, single-arm, phase II trial that investigated the combination of epcoritamab with R-miniCVP (r...
Walter Weber, MD, on Implant-Based Breast Reconstruction Techniques After Mastectomy
Walter Weber, MD, of University Hospital Basel, presents data from the international randomized phase III PREPEC trial (OPBC-02), which found prepectoral implant-based breast reconstruction (IBBR) sig...
Laura Alder, MD, on New Data on Combination Therapy, Immunotherapy, and ADCs in Small Cell Lung Cancer
Laura Alder, MD, of Duke University Medical Center, highlights emerging data discussed in the meeting’s oral abstract session on small cell lung cancer, including increased toxicity without efficacy b...
Lucy Gilbert, MD, on Overall Survival by Prior Taxane Use in the Phase III ROSELLA Trial
Lucy Gilbert, MD, of McGill University Health Centre, discusses subgroup analyses from the ROSELLA study. Relacorilant plus nab-paclitaxel demonstrated a statistically and clinically significant overa...
Jamie E. Chaft, MD, FASCO, on Nivolumab After Surgery and Adjuvant Chemotherapy in NSCLC
Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses findings from ECOG-ACRIN EA5142/ALCHEMIST, a phase III randomized trial that evaluated the efficacy of adjuvant nivoluma...
Mohammed Al-Jumayli, MD, on a Digital Prehabilitation Model in Older Adults Undergoing Hepatobiliary Cancer Surgery
Mohammed Al-Jumayli, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses the effects of the use of a multimodal, digitally supported prehabilitation program among adults aged 65 year...
William G. Wierda, MD, PhD, on Pirtobrutinib in Treatment-Naive Patients With CLL/SLL
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, presents pooled results from the BRUIN CLL-313 and BRUIN CLL-314 trials. BRUIN CLL-313 is comparing pirtobrutinib to b...
Lorenza Rimassa, MD, and David James Pinato, MD, PhD, on Expanding the HCC Treatment Landscape: TACE Combinations, Immunotherapies, and Bispecific Antibodies
Lorenza Rimassa, MD, of IRCCS Humanitas Research Hospital, and David James Pinato, MD, PhD, of Imperial College London, discuss positive phase III findings in intermediate-stage hepatocellular carcino...
John V. Heymach, MD, PhD, on First-Line Therapy for Advanced NSCLC With EGFR Exon 20 Insertions
John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the primary analysis of the multinational phase III WU-KONG28 trial, which looked at sunvozertini...
Shubham Pant, MD, MBBS, on Novel RAS-Targeting Therapy Daraxonrasib Doubles Overall Survival in Metastatic Pancreatic Cancer
Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses the practice-changing results of the phase III RASolute 302 study, which showed that daraxonrasib doubled median...
Mazyar Shadman, MD, on CLL/SLL: Sonorotoclax and Zanubrutinib
Mazyar Shadman, MD, of the University of Washington and Fred Hutchinson Cancer Center, describes the safety and efficacy results of the all-oral first-line combination regimen of sonrotoclax and zanub...
Erika P. Hamilton, MD, FASCO, on HER2-Positive Metastatic Breast Cancer: Maintenance Therapy Comparison
Erika P. Hamilton, MD, FASCO, of Sarah Cannon Research Institute, talks about a comparison of the efficacy and safety of tucatinib vs placebo combined with trastuzumab and pertuzumab as maintenance th...
Elena Elimova, MD, on PD-L1 Subgroup Analysis From HERIZON-GEA-01
Elena Elimova, MD, Princess Margaret Cancer Centre, discusses the efficacy in PD-L1 subgroups of zanidatamab plus chemotherapy with or without tislelizumab as a first-line regimen for HER2-positive lo...
Yashasvini Sampathkumar, MD, on Job Retention Intervention for Patients Undergoing Breast Cancer Therapy: Digital vs Print Format
Yashasvini Sampathkumar, MD, of Memorial Sloan Kettering Cancer Center, presents data on Talking to Employers and Medical Staff about Work (TEAMWork), an English/Spanish intervention. The English/Span...
Giannis S. Mountzios, MD, on SCLC: Intracranial Effect of Tarlatamab vs Chemotherapy
Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, discusses findings from a post hoc analysis of the phase III DeLLphi-304 trial, which examined the intracranial efficacy of tarlatamab vs che...
Ramaswamy Govindan, MD, FASCO, on EGFR-Mutant NSCLC: Final Overall Survival Results From Alliance A081105
Ramaswamy Govindan, MD, FASCO, of Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis, presents the final overall survival results from the randomized phase III All...
Lauren Averett Byers, MD, on ABBV-706 in Relapsed or Refractory SCLC
Lauren Averett Byers, MD, of The University of Texas MD Anderson Cancer Center, describes data on ABBV-706—an investigational antibody-drug conjugate targeting SEZ6—alone or in combination with the an...
Asaf Maoz, MD, on Pancreatic Cancer Screening: Potential Blood-Based Biomarkers
Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveil...
Robert C. Stein, PhD, MBBChir, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Test-Directed Chemotherapy
Robert C. Stein, PhD, MBBChir, FRCP, of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, discusses the first results from the phase III random...
Marlana M. Orloff, MD, on Metastatic Uveal Melanoma: First-Line Therapy for HLA-A2–Negative Disease
Marlana M. Orloff, MD, of Thomas Jefferson University Hospital, reviews primary results from the OptimUM-02 trial, which investigated the doublet of darovasertib plus crizotinib vs investgator’s choic...
Linda R. Mileshkin, MD, MBBS, FRACP, on Puxitatug Samrotecan for Endometrial or Ovarian Cancer
Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisome...
Kevin Kalinsky, MD, MS, FASCO, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-04
Kevin Kalinsky, MD, MS, FASCO, of Winship Cancer Institute of Emory University, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among pat...
Yelena Y. Janjigian, MD, FASCO, on Safety Results From DESTINY-Gastric03
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses safety results for DESTINY-Gastric03 Part 2 (arms D and F) and Part 4. The trial evaluated first-line fam-trastuzum...
Brendan Heiden, MD, on Lung Cancer Screening Eligibility: Smoking Duration vs Pack-Years
Brendan Heiden, MD, of Washington University School of Medicine, discusses data from a unique real-world cohort of nearly 1 million patients in the Veterans Health Administration; researchers evaluate...
